Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Express Co (AXP) vs Novavax Inc (NVAX) Price & Performance

American Express CoTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

American Express Co vs Novavax Inc — how do they compare? American Express Co trades at $343.32 (market cap $230.15B), while Novavax Inc trades at $7.94 (market cap $1.31B). The key difference: American Express Co is far larger — about 175.7× Novavax Inc's market cap, and American Express Co pays a 1.11% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

AXPNVAX
Market Cap
$230.15B$1.31B
Sector
FinancialsHealth
52-Week High
$384.82$11.19
52-Week Low
$292.27$6.22
Dividend Yield
1.11%
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Express Co

AXP trades at $343.22, up 1.29% today, with a bullish technical signal and strong support at $339. The stock shows robust fundamentals with 2025 revenue of $72.23B and net income of $10.83B, though recent earnings have been mixed. Analyst consensus is a $369.42 price target with 40% buy ratings. Recent news highlights Amex Ventures' AI investments and premium cardmember benefits, reinforcing growth initiatives.

Outlook remains positive due to steady revenue growth and high ROE of 33.97%, but risks include competitive pressures and a P/E of 20.68 above sector averages. The stock offers upside to consensus targets if execution continues, though investors should monitor spending trends and economic sensitivity.

Novavax Inc

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Express Co

American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.

Read more on AXP

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX